1. ALLA AKTIER
  2. NYHETER
  3. ONCOPEPTIDES

Oncopeptides

Nyheter Oncopeptides Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Number of shares and votes in Oncopeptides

LHFI

Stockholm – March 31, 2026 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the number of shares and votes in Oncopeptides has changed as a result of the rights issue which ended on March 16, 2026.

After the rights issue, the total number of shares in Oncopeptides amounts to 395,287,003 shares, of which 381,148,118 are ordinary shares and 14,138,885 are class C shares. After the rights issue, the total number of votes in Oncopeptides amounts to 382,562,006.5. The share capital has increased by SEK 13,620,072.330911 from SEK 30,300,707.563894 to SEK 43,920,779.894805.

For more information, please contact:
David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)
E-mail: ir@oncopeptides.com
Cell phone: +46 76 229 38 68

This information is information that Oncopeptides is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-03-31 08:30 CEST.

About Oncopeptides
Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. 

The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.

Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.

The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.

For more information see: www.oncopeptides.com

Attachments
Number of shares and votes in Oncopeptides

Datum 2026-03-31, kl 08:30
Källa MFN
Bifogade filer
Number of shares and votes in Oncopeptides